Bizaxofusp in rGBM Patients Versus a Propensity Matched External Control Arm: Designing a Novel Phase 3 Trial with the FDA

Time: 9:30 am
day: Conference Day One


  • Present design, mechanism, delivery and safety of bizaxofusp, an IL-4/IL-13R empowered superkine
  • Summarize Phase 2b trial comparing bizaxofusp versus a propensity matched external control arm and effect of MGMT methylation, dose, IL4R expression, and combination with bevacizumab on median survival
  • Overview of a novel Phase 3 registration trial using a Hybrid External Control Arm